

Tracleer - (32 mg; Tablet for suspension, Oral)

Generic Name	Bosentan	Innovator	Actelion pharmaceuticals
Dosage	32 mg; Tablet for suspension, Oral	Branded US Sales	Less Than \$1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	Less Than 5
Final Approvals	Less Than 5	Generic Launches	None
Indication	Indications for Tracleer: -Pulmonary arterial hypertension (PAH) (WHO Group I) in adults with WHO Class II–IV symptoms to improve exercise ability and decrease clinical worsening		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact $\underline{contact@researchdelta.com}$ to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact $\underline{contact@researchdelta.com}$ to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.